sST2 as a value-added biomarker in heart failure

Area of Science:

• Biomarker Discovery and Validation
• Cardiovascular Medicine
• Translational Research

Background:

• Soluble suppression of tumorigenicity-2 (sST2) is increasingly recognized for its role in fibrosis and inflammation.
• Understanding sST2's clinical utility is crucial for advancing cardiovascular disease management.
• Current HF biomarkers face interpretation challenges due to comorbidities.

Purpose of the Study:

• To review recent findings on the biomarker sST2.
• To highlight sST2's utility in complex HF cases.
• To explore sST2's potential in heart failure with preserved ejection fraction (HFpEF).

Main Methods:

• Literature review of recent studies on sST2.
• Analysis of sST2's independence from common comorbidities (e.g., renal dysfunction, hypertension).
• Evaluation of sST2's role in specific patient populations, including HFpEF.

Main Results:

• sST2 is a promising biomarker for heart failure (HF) management.
• sST2 levels are independent of common comorbidities like renal dysfunction and hypertension.
• sST2 shows potential for combined use with natriuretic peptides, especially in HFpEF.

Conclusions:

• sST2 offers a valuable tool for HF diagnosis and management, particularly when other biomarkers are unreliable.
• Its independence from comorbidities makes it a robust marker across diverse patient groups.
• Monitoring sST2 kinetics can aid in treatment customization and clinical decision-making for heart failure patients.